The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services globally to companies within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS technology (IVRS/IXRS) through to commercial-scale manufacture and companion diagnostic development.
Paul Skultety, Alex McClung, Ted Koontz and Damian Gant, Xcelience, a division of Capsugel Dosage Form Solutions||May 5, 2016 What does a one-stop shop really mean and is it always best for the client?
Tim Wright, Editor||March 9, 2016 Contract Pharma asked a roundtable of business leaders from Symbiosis, Grifols, Althea, LSNE and Baxter to discuss key trends in the parenteral dosage development and manufacturing market
James E. Gregory, UPM Pharmaceuticals||October 7, 2015 Pharmaceutical and biopharmaceutical companies large and small are increasingly relying on third-party providers for support at all stages of drug development. To realize efficiencies, they are at the same time reducing the number of suppliers to a preferred few with whom they can form strategic partnerships.
Julie Kuriakose , UPM Pharmaceuticals ||May 1, 2014 Comparing manufacturing methods for one immediate-release low-dose form, we found that dry blend needed less equipment and was more “QbD-ready” than wet granulation or geometric dilution.